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Summary
Objective: To evaluate the effect of calcitonin (CT) on the histology and biochemistry of articular cartilage from unstable operated and
nonoperated knee in a canine model of experimental osteoarthritis (OA).
Methods: Eighteen dogs underwent anterior cruciate ligament transection (ACLT) of the right knee and were randomly distributed into three
groups of six dogs each. From day-1 after surgery until sacriﬁce 84 days post-ACLT, each dog received a daily nasal spray that delivered the
placebo, 100 units of CT or 400 units of CT. Histologic lesions were scored. Hyaluronan (HA) and antigenic keratan sulfate (AgKS) were
quantiﬁed by enzyme-linked immunosorbent assays (ELISAs), whereas aggrecan molecules extracted under nondissociative conditions were
characterized by velocity gradient centrifugation.
Results: All canine cruciate-deﬁcient knees developed OA. At a daily dose of 400 units, CT had no effect on the size of osteophytes but
signiﬁcantly reduced the severity of cartilage histologic lesions in unstable knees. CT also enhanced the HA content as well as the size
distribution and relative abundance of fast-sedimenting aggrecan aggregates in cartilage from both operated and nonoperated knees. On the
other hand, in the CT-treated group, the cartilage content of AgKS increased in operated joints, but not in nonoperated joints.
Conclusions: Because CT delivered as a nasal spray markedly reduced the severity of most OA changes, both at the histological and
biochemical level, this form of therapy may have beneﬁts for humans who have recently experienced a traumatic knee injury, and as well as for
dogs who spontaneously rupture their ACL.
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Cartilage
Repair
SocietyIntroduction
Although it is generally believed that chondrocyte-mediated
degradation of the cartilage matrix is a major pathologic
change in osteoarthritis (OA)1,2, it is also increasingly
recognized that other joint components contribute to the
progression of the disease process. Indeed, in patients with
established OA of the knee, disease progression is
associated with a sustained increase in serum levels of
hyaluronan (HA), a marker of synovial proliferation and
hyperactivity3,4. Further, in knee OA, increased uptake of
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Received 18 December 2003; revision accepted 11 August 2004.904technetium-labeled bisphosphonate, which correlates with
synovial ﬂuid markers of cartilage and bone turnover,
predicts subsequent joint space narrowing and, hence,
cartilage loss5,6. Therefore, the therapeutic target in OA
should not be restricted to articular cartilage, but should
encompass other joint components including bone.
Difﬁculty in obtaining joint tissue from human OA joints
before the disease is far advanced has stimulated the
creation of animal models that simulate the human
condition. Although these models must always be viewed
with caution, they nevertheless improve our understanding
of parallel pathologic changes in humans and allow the
identiﬁcation of early and important features of joint
degeneration. Among the many animal models of exper-
imentally induced OA currently available, the resection of
the anterior cruciate ligament in the dog is well estab-
lished7,8. Joint instability appears to be the initiating factor in
905Osteoarthritis and Cartilage Vol. 12, No. 11the induction of cartilage lesions that closely resemble
those of natural canine OA.
Previous studies have pointed out that in canine
experimental OA, cartilage biochemical changes occur
before cartilage morphological changes7 and include a re-
duction in the HA content of cartilage matrix, a reduction in
the antigenic keratan sulfate (AgKS) content of aggrecan
molecules, as well as the progressive disappearance of the
fast-sedimenting link protein-rich aggrecan aggregates9e11.
These ﬁndings are worth stressing since similar changes in
the biochemical composition and in the supramolecular
organization of proteoglycan (PG) aggregates have also
been observed in human OA cartilage12,13. Therefore, as in
canine experimental OA, calcitonin (CT) not only markedly
reduces the urinary levels of deoxypyridinoline, a speciﬁc
marker of bone resorption, but also causes signiﬁcant
decreases in the severity of the OA cartilage changes as
well as in the circulating blood levels of HA14. The present
investigation was undertaken to determine to what extent
this hormone might prevent, at least in part, these important
biochemical OA changes in cartilage from canine cruciate-
deﬁcient knees.
Material and methods
MATERIALS
Highly puriﬁed collagenase (form III) was from Advance
Biofactures Corp. (New York, NY, USA). All other reagents
were of analytical grade and supplied by SigmaeAldriche
Fluka (Bornem, Belgium).
Eighteen sets of vials for nasal spray delivery were kindly
provided by Novartis (Basel, Switzerland). Six sets con-
tained a placebo, six other sets were conditioned to deliver
100 units of salmon CT per spray and the last six sets were
conditioned to deliver 400 units of salmon CT per spray.
The sets were randomly numbered from 1 to 18 and
shipped to the investigators. The authors were blinded to
the content of each set during the entire period of the study
and they were only informed after having entered the results
of all parameters under study in a computer database.
ANIMAL PROTOCOLS
Animal housing and handling were conducted according
to the rules and regulations of the Belgian Federal State. A
total of 18 beagle dogs, approximately 4 years of age, were
used. Each dog was randomly assigned a number ranging
from 1 to 18 and, after quarantine and conventional health
measures, the anterior cruciate ligament of the right knee
was severed as previously reported3,9. The dogs were
allowed to exercise for at least 1 h per day and were
sacriﬁced on day-84 after surgery. Beginning on day-1 post-
surgery through the end of the study time period, each
animal received a daily nasal spray from the set of vials
corresponding to its identiﬁcation number.
JOINT EXAMINATION AND CARTILAGE TISSUE SAMPLING
After careful opening of the joint, synovial ﬂuid was
collected from both the operated and nonoperated knee of
each animal and the volume of ﬂuid was measured.
Osteophyte formation was graded by measuring the
maximal width (in mm) of the spur on each femoral
trochlear ridge and the mean value was recorded. Cartilage
damage on the femoral condyles and tibial plateaus wasgraded using a dissecting microscope. The surface of each
erosion was measured and expressed in mm2 before
summing to yield the total surface of erosions. The depth
of cartilage erosions was graded on a scale of 0e4, where
0 represented normal appearance and 4, a cartilage erosion
extending to the subchondral bone. Macroscopic changes
in the joints were scored by two independent observers,
who noted similar values. We report here, in each case, the
mean of the two scores.
Immediately after scoring, the medial femoral condyle
from both knees was removed en bloc, ﬁxed in 10%
buffered formalin containing 5% cetylpyridinium chloride
and shipped to Dr J. M. Williams, who was blinded to the
interventions. Each specimen was scored according to the
histologicehistochemical scale of Mankin et al.15.
To circumvent depth-related variations, the whole carti-
lage thickness was sampled from the lateral femoral
condyles for biochemical analysis and from the tibial
plateaus for the characterization of aggrecan molecules.
BIOCHEMICAL ANALYSES
Cartilage specimens dissected from femoral condyles
were lyophilized and weighed to obtain dry weights. They
were then digested with twice-crystallized papain (100
mg/ml) in 0.15 M sodium acetate, 20 mM cysteine HCl, pH
6.0, for 24 h at 60(C. After digestion, the materials were
centrifuged at 12,000! g for 15 min.
Aliquots of the digests were analyzed for hydroxyproline
content using the method of Woessner16. The collagen
content was then calculated from the hydroxyproline con-
tent, by multiplying the latter by 8.33. The PG and chond-
roitin sulfate contents were measured by the previously
described dimethylmethylene blue assay17, using puriﬁed
preparations of bovine nasal puriﬁed PG monomers and
chondroitin sulfate as standards.
Antigenic (Ag) KS and HA were quantiﬁed by well-
characterized enzyme-linked immunosorbent assay
(ELISA) procedures18,19. All measurements in the AgKS
inhibition ELISA refer to equivalents of an International
Standard, kindly donated by Drs M. B. Mathews and A. L.
Horwitz, The University of Chicago, Chicago, IL, USA. The
relative percentage of AgKS found in PGs was expressed
as the ratio of the AgKS concentration (weight/volume)
relative to the sum of the concentrations (weight/volume) of
chondroitin sulfate and AgKS.
EXTRACTION, PURIFICATION AND CHARACTERIZATION
OF AGGRECAN MOLECULES
After sampling cartilage from both the medial and lateral
areas of tibial plateaus that are covered by menisci, slices
of cartilage specimens were incubated at 37(C for 6 h with
a highly puriﬁed collagenase (1000 units per 100 mg wet
weight cartilage) and a mixture of protease inhibitors20. The
solubilized aggrecan molecules were then puriﬁed by two
successive equilibrium density gradient centrifugations in
cesium sulfate and cesium chloride, respectively. The
puriﬁed a-A1 aggrecan molecules were dialyzed against
a buffer containing 50 mM sodium acetate, 10 mM sodium
EDTA, 100 mM E-aminocaproic acid, 10 mM N-ethylmalei-
mide, 5 mM benzamidine HCl, 5 mM phenylmethylsulfonyl
ﬂuoride and 5 mM iodoacetamide, pH 5.8 (Buffer A). The
aggrecan concentration was adjusted to 0.1e0.3 mg/ml
in Buffer A prior to characterization by velocity
gradient centrifugation. These low aggrecan concentrations
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otherwise necessary extrapolation to zero concentration. In
this centrifugal method, the aggrecan preparations are
centrifuged in a preformed cesium sulfate density gradient,
and, at the end of centrifugation, the determination of the
hexuronate distribution throughout the centrifuge tube
allows the calculation of the differential distribution function
g(S )Z dG(S )/ds as described previously20,21. This meth-
odology appears very precise and efﬁcient for the centrif-
ugal characterization of aggrecan preparations.
STATISTICAL ANALYSIS
After entering all measured data in a computer database
(statistical software Prism from GraphPad, version 3.0,
San Diego, CA), the randomization of the CT preparations
was revealed by Novartis to allow the comparison of data
obtained in the three groups of animals: the group having
received the placebo, the group having received a daily
dose of 100 units of salmon CT, and the group having
received a daily dose of 400 units of salmon CT. Compar-
isons among the three groups involved the estimation of
mean, standard deviation (SD), and analysis of variance
followed by post hoc testing (Tukey). A P value of less than
0.05 was considered as statistically signiﬁcant.
Results
MORPHOLOGICAL FINDINGS
Only small volumes of synovial ﬂuid (0.1e0.3 ml) were
collected from the nonoperated knees of the animals in all
three groups. Higher volumes were obtained from the
operated knees (Fig. 1, upper left panel), ranging from 1.2
to 2 ml (mean: 1.5 ml) in the placebo-treated-group, from0.5 to 2 ml (mean: 1.1 ml) in the 100 units CT-treated group
and from 0.5 to 1.2 ml (mean: 0.8 ml) in the 400 units CT-
treated group. Although treatment with CT was associated
with a reduction in synovial ﬂuid volume, a statistically
signiﬁcant decrease was only detected in the group treated
with 400 units of CT when compared to the placebo group
(P! 0.05).
The nonoperated knee joints from animals in all three
groups were macroscopically normal. In the operated
knees, the width of femoral osteophytes was distributed
over a wide range of values in the three groups: 3e7 mm in
the placebo-treated group (mean: 4.5 mm), 2e6 mm (mean:
3 mm) in the 100 units CT-treated group and 2e6 mm
(mean: 3.5 mm) in the 400 units CT-treated group. No
statistically signiﬁcant differences were found between the
three groups.
On the other hand, treatment with CT signiﬁcantly
reduced the mean size of both femoral condyle and tibial
plateau cartilage ulcerations (Fig. 1, upper right and lower
left panels, respectively). Furthermore, in the tibial plateau,
but not in the femoral condyles, the mean size of ulcerations
was signiﬁcantly smaller in the group treated with 400 units
of CT than in the group treated with 100 units of the
hormone (P! 0.05). The grade of cartilage erosion seen in
the femoral condyles and tibial plateaus ranged from 1 to 2
(mean: 1.5) in the placebo-treated group and was scored as
1 in all the animals treated with 400 units of CT (data not
shown).
Medial femoral condyle specimens from the operated
knees of the placebo-treated group all exhibited histological
changes compatible with OA. As shown in Fig. 1 (lower right
panel), the operated knee Mankin score was, however,
signiﬁcantly reduced in both the 100 units (P! 0.001) and
400 units CT-treated groups (P! 0.001) when compared to
the placebo-treated group. There was no statisticallySynovial fluid
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Fig. 1. Macroscopic and microscopic ﬁndings in the operated knees from animals treated daily with either the placebo, 100 units (U) of
calcitonin or 400 U of calcitonin, and sacriﬁced on day-84 after surgery. The histologicehistochemical scale of Mankin was assessed on
cartilage sampled from the medial femoral condyle. The horizontal lines represent mean values. The P value was determined by the Tukey’s
test following ANOVA.
907Osteoarthritis and Cartilage Vol. 12, No. 11signiﬁcant difference in the mean Mankin scores of the
operated knees between the two groups treated with 100
and 400 units of CT. In contrast, no histologic abnormality
could be detected in the femoral condyle specimens from
nonoperated knees in all three groups (data not shown).
BIOCHEMICAL FINDINGS
As stressed by Maroudas22, wet weight determinations of
OA cartilage can be misleading because cartilage slices
lose water relatively easily when exposed to air. Further, in
contrast to normal articular cartilage, OA cartilage swells
considerably when equilibrated in physiologic saline sol-
utions. Accordingly, the collagen, PG and HA contents all
were expressed per unit dry weight (Fig. 2) when comparing
the concentrations of these molecules in cartilage speci-
mens from operated and nonoperated knees.
Comparisons between the placebo-treated group and the
two CT-treated groups disclosed that, in cartilage sampled
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Fig. 2. Parameters of the biochemical composition of cartilage
specimens sampled from the lateral femoral condyle of the operated
knees (C, closed circles), all of which developed OA, and the
nonoperated knees (B, open circles) of placebo- and calcitonin
(CT)-treated [100 or 400 units (U) ] dogs. Each point represents the
mean of three determinations made on a given animal. In each
scatter plot, the horizontal line represents the mean value. The
P value was determined by the Tukey’s test following ANOVA.from the lateral femoral condyle, animals treated with CT
exhibited a signiﬁcant increase in the mean collagen
content of their operated knees, all of which developed
OA (Fig. 2, upper panel), but not of their nonoperated
control knees. However, even at a daily dose of 400 units,
the hormonal treatment was unable to eliminate the
statistically signiﬁcant difference in the mean collagen
content of cartilage specimens from operated OA joints
and nonoperated joints (P! 0.05) (Fig. 2, upper panel).
In the placebo-treated group, the cartilage sampled from
the operated knees, all of which developed OA at 12 weeks
post-surgery, exhibited a higher PG content than the
cartilage sampled from the nonoperated knees (P! 0.05;
Fig. 2, middle panel) whereas in the two groups treated with
CT, there was no statistically signiﬁcant difference in the
mean PG content of cartilage between the operated and
nonoperated knee joints. Further comparison between the
PG content of cartilage from operated and nonoperated
knees disclosed that, at a daily dose of either 100 or
400 units, CT enhanced signiﬁcantly the mean PG content
of nonoperated knees (P! 0.05) but had no effect on the
mean PG content of operated knees.
At a daily dose of 100 units, CT had little effect on the
mean HA content in cartilage sampled from the lateral
femoral condyle of either operated OA or nonoperated
knees, whereas, at a daily dose of 400 units, the mean HA
content was signiﬁcantly enhanced in cartilage sampled
from both operated OA and nonoperated knees (Fig. 2,
lower panel). It is worth noting that cartilage specimens from
the operated OA knees of the 400 units CT-treated group
exhibited HA contents (mean and range of values: 1.5;
1e2 mg/mg tissue dry weight, respectively) similar to those
observed for the cartilage tissue from the nonoperated
knees of the placebo-treated group (mean and range of
values: 1.6; 1.1e2.1 mg/mg tissue dry weight, respectively)
(Fig. 2, lower panel).
In the placebo-treated group, the mean AgKS content of
PGs present in cartilage sampled from the lateral femoral
condyle of operated OA knees was signiﬁcantly lower than
the mean AgKS content of PGs present in cartilage
sampled from the same region of nonoperated knees
(Fig. 3). On the other hand, treatment with CT was unable
to change the mean AgKS content of PGs sampled from the
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Fig. 3. Relative content of antigenic keratan sulfate (AgKS) of cartilage
proteoglycan (PG) molecules, expressed as the ratio of AgKS to total
sulfated glycosaminoglycans (chondroitin sulfate (CS)C AgKS),
which were sampled from the operated OA (C, closed circles) and
nonoperated (B, open circles) knees of animals treated daily with
either the placebo, 100 units (U) or 400 U of calcitonin. Each point
represents the mean of three determinations made on a given animal.
The horizontal line represents the mean value. The P value was
determined by the Tukey’s test following ANOVA.
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of 400 units, enhanced markedly the mean AgKS content of
PGs sampled from operated OA knee joints. It is worth
stressing that, in the 400 units CT-treated group, the mean
AgKS content of PGs was similar in both operated OA and
nonoperated joints (25% vs 28.5%, respectively) and
amounted to a value close to that observed for PGs
sampled from the nonoperated knees of the placebo-
treated group.
CENTRIFUGAL CHARACTERIZATION OF THE PG MOLECULES
RECOVERED UNDER NONDISSOCIATIVE CONDITIONS FROM
CARTILAGE OF OPERATED AND NONOPERATED JOINTS
Centrifugal studies were restricted to the cartilage PGs
recovered from the tibial plateaus of dogs that were treated
daily with the placebo or 400 units of CT.
As previously observed12, pretreatment of cartilage
specimens with highly puriﬁed collagenase in the presence
of selected protease inhibitors yielded, in low ionic strength
solutions, 60% to 70% of the total tissue hexuronate. After
puriﬁcation by two successive equilibrium density gradient
centrifugations in different cesium salts, the nondissociated
(a-A1 preparations) PG molecules recovered from the
different cartilage specimens were characterized by velocity
gradient centrifugation. In each group, the sedimentation
proﬁles observed for the different a-A1 preparations of
operated and nonoperated joints were averaged to gener-
ate the representative g(S ) distribution curves shown in
Fig. 4. In all a-A1 specimens, the PG molecules were
distributed into three well-deﬁned sedimenting modes: themonomers (PG-M), with an average sedimentation co-
efﬁcient of 16 S, the intermediate size or slow-sedimenting
(PG-A1) aggregates ranging from 35 to 60 S and the more
saturated or fast-sedimenting (PG-A2) aggregates ranging
from 60 to about 120 S.
In the placebo-treated group, the sedimentation proﬁle of
a-A1 preparations from operated OA joints (Fig. 4, upper
right panel) differed markedly from that of a-A1 preparations
from nonoperated joints (Fig. 4, upper left panel). In
agreement with previous studies12,14, the a-A1 preparations
from operated OA joints contained predominantly mono-
mers (P! 0.05). Further comparison between the a-A1
preparations from operated and nonoperated joints showed
that, in preparations from operated joints, the proportion of
PG-A1 aggregates was signiﬁcantly reduced (mean: 36%
vs 46% for nonoperated joints; P! 0.05) whereas their PG-
A2 aggregates were consistently smaller (mean: 70 S vs
87 S for nonoperated joints; P! 0.05) and less abundant
(mean: 7% vs 22% for nonoperated joints; P! 0.05).
In contrast, in the CT-treated group (400 units), the
differences in the sedimentation proﬁle between the a-A1
preparations recovered from operated OA knees (Fig. 4,
lower right panel) and the a-A1 preparations recovered from
nonoperated knees (Fig. 4, lower left panel) were less
striking. In both preparations, the majority of PG molecules
were present as aggregates. However, in preparations from
nonoperated joints, the mean percentage of PG-Ms was
signiﬁcantly reduced (25% vs 41%; P! 0.05) whereas the
mean percentage of PG-A1 was signiﬁcantly increased
(48% vs 41%; P! 0.05). Further comparison between a-A1
preparations from both joints disclosed that the PG-A2Left nonoperated knee :
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Fig. 4. Averaged centrifugal distribution curves from results of boundary sedimentation analyses of cartilage proteoglycans (PGs) recovered
under nondissociative conditions from nonoperated and operated OA knees of dogs treated daily with either the placebo or 400 units of
calcitonin (CT) and then sacriﬁced on day-84 after surgery. For each curve and from left to right, the ﬁrst peak represents the PG monomers
(PG-M), the second peak represents the intermediate size or slow-sedimenting (PG-A1) aggregates and the third peak represents the more
saturated or fast-sedimenting (PG-A2) aggregates (range of values).
909Osteoarthritis and Cartilage Vol. 12, No. 11aggregates were larger (mean: 93 S vs 77 S; P! 0.05) and
more abundant (mean: 27% vs 18%; P! 0.05) in prepa-
rations from nonoperated knees.
Obviously, treatment with CT induced marked changes in
the sedimentation proﬁle of a-A1 preparations from both
nonoperated and operated OA joints. Indeed, in both joints,
administration of the hormone led to a decrease in the mean
abundance of PG-Ms (P! 0.01 for both joints) and
concomitantly enhanced the mean percentage of PG-A1
aggregates (P! 0.05 for nonoperated joints and P! 0.01
for operated OA joints). Further, although the hormone
treatment was associated with an increase in both the mean
size and mean percentage of PG-A2 aggregates from both
knees, a statistically signiﬁcant difference between placebo-
and CT-treated groups was only observed in the operated
OA knees for both the mean size (P! 0.01) and the mean
percentage (P! 0.01).
Discussion
The results of the double-blinded prospective study
presented here indicate that, in the early stages of canine
experimental OA, the daily nasal administration of 400 units
of CT markedly slowed down the development of most
cartilage degenerative changes. The order of magnitude of
biochemical and morphologic changes observed in carti-
lage from operated OA knees is similar to that observed in
previous studies at a similar time period post-
surgery7,9e13.
These results not only conﬁrm a previous report showing
that in the same animal OA model the subcutaneous
administration of CT signiﬁcantly reduced the severity of
cartilage microscopic OA changes14, but they also clearly
demonstrate that the hormonal treatment was accompanied
by striking changes in the biochemical composition and
supramolecular organization of articular cartilage from OA
knees. The fact that the treatment with CT was effective in
reducing the net loss of HA and collagen associated with
the development of OA changes is, by itself, a ﬁnding of
singular signiﬁcance. Given the critical functional properties
of aggrecan molecules that populate cartilaginous struc-
tures, the discovery that this treatment also was successful
in reducing the increase in the relative proportion of
aggrecan monomers as well as the concomitant decrease
in the relative proportion of PG aggregates of large sizes is
likely to be of great interest to both clinicians and scientists.
Although, for practical reasons, biochemical determinations
were conducted on cartilage from femoral condyles and
centrifugal analyses were restricted to PGs extracted from
tibial plateaus, our ﬁndings remain meaningful because in
canine experimental OA, changes in gene expression and
the biochemical composition of articular cartilage occur
throughout the entire compartment of the OA joint7e11,24. In
contrast to its marked effects on the biochemical compo-
sition and supramolecular organization of cartilage, CT,
a potent inhibitor of bone osteoclastic resorption, had no
effect on osteophyte formation. This lack of pharmacologic
effect on osteophytosis should not be surprising since
osteophyte formation involves bony metaplasia of new
ﬁbrous connective tissue and is not reliant on bone
resorption.
CT added to the medium in which articular chondrocytes
are cultured enhances PG synthesis in a dose-dependent
manner25. In our animal model of OA, treatment with CT
caused an increase in PG content of articular cartilage, but
this was limited to the nonoperated joint examined. Thefailure of CT to enhance the PG content of cartilage from
operated OA joints might reﬂect, at least in part, the fact that
chondrocytes in these joints already are maximally stimu-
lated to synthesize these functional matrix molecules. This
stimulation of PG synthesis, which is sustained for as long
as 64 weeks after surgery8,23, usually overcompensates for
increased PG degradation and leads to the increase in the
PG content of OA cartilage seen in this study and other
reports11,23. This phenomenon, termed hypertrophic repair,
is not restricted to canine OA but has also been observed in
other animal models of OA and in human OA as well, at
least until the late stages of the disease process26.
Further, although CT seems to have no effect on the PG-
degrading activity secreted by chondrocytes27, bone cells
derived from human OA joints secrete an as yet undeﬁned
factor that inﬂuences the metabolism of cartilage ex-
plants28. Should such factors normally be sequestered
within the bone matrix in vivo, the CT-induced suppression
of osteoclastic bone resorption would have inhibited the
release of this factor.
Despite its enhanced PG content, hypertrophic OA
cartilage does not withstand mechanical stress as well as
normal hyaline cartilage29,30 and full-thickness loss of
cartilage tissue develops with time post-surgery8. These
observations may be related, at least in part, to the
reduction in content of HA9,12, the backbone upon which
aggrecan molecules align to form aggregates, and to the
progressive depletion of the fast sedimenting or more
saturated PG aggregates10,13 seen in canine OA cartilage
and human OA cartilage as well. HA not only helps to ﬁrmly
immobilize PGs at high concentrations within the collagen
network, but it also dramatically increases the rheological
properties of PG molecules31. Accordingly, the reduction in
HA content, accompanied by a reduction in the relative
abundance and size distribution of PG aggregates is likely
to markedly reduce the viscoelastic properties of articular
cartilage and, in so doing, to contribute to the apparent
irreversibility of the OA disease process. The key contrib-
utory role that the decrease in HA content may play in OA
progression is exempliﬁed by the fact that the content of HA
in articular cartilage remains normal in disuse atrophy,
a condition in which the chondrocytes are able to overcome
the loss of PGs that ensues as a result of increased enzyme
activities11.
The mechanisms responsible for the HA depletion seen
in OA cartilage remain unclear. As the loss of HA from OA
cartilage explants occurs in spite of an upregulation in HA
biosynthesis32,33, a likely explanation is that HA strands are
being degraded at an accelerated rate by a hyaluronidase.
The problem is that no hyaluronidase activity at near neutral
pH has been thus far identiﬁed in normal and OA cartilage.
An alternative explanation is that the decrease in HA
content is connected to an increase in internalization of HA
and its degradation to small oligosaccharides within a low
pH lysosomal compartment, with the endocytosis being
mediated via cell surface CD44/HA receptors34.
In CT-treated dogs, the HA content of cartilage remained
higher in the nonoperated joints than in operated OA joints,
suggesting that the hormone was unable to completely
inhibit the mechanisms responsible for the relative depletion
of HA in OA cartilage. This notwithstanding, the results also
showed that by enhancing the HA content in cartilage from
both operated OA and nonoperated canine knees, CT
increased the relative amounts of PG aggregates observed
in both joints. One may postulate, therefore, that by
improving the resistance of the articular tissue to the
considerable stresses and strains arising from joint loading,
910 H. El Hajjaji et al.: Calcitonin and canine experimental OACT treatment contributed to the observed reduction in the
score of the OA microscopic lesions.
Measurement of the AgKS content of aggrecan mono-
mers revealed that the administration of CT also appeared to
affect the quality of the PGs synthesized by chondrocytes in
the operated OA joint. The fact that the content of AgKS in
cartilage within the operated OA joint of animals treated with
CT did not decrease, as it did in animals not receiving the
hormone, is interesting. Our original observation that the
content of AgKS in aggrecan decreases with the de-
velopment of degenerative changes in this canine model
of OA10 led us to suggest that these chondrocytes switch to
the synthesis of an ‘‘immature’’ PG, which resembles the
chondroitin sulfate-rich aggrecan molecules produced by
fetal chondrocytes. The ﬁndings presented here, therefore,
suggest that CT is able to inﬂuence not only the quality of the
PG aggregates in OA tissue but also that of the aggrecan
monomer synthesized by the cells. While the content of
AgKS in aggrecan is not thought to vary markedly during
adult life18 one cannot rule out at this stage the possibility
that these observed changes in AgKS content reﬂect, in part,
a decrease in the size or sulfation of KS chains.
The disruption and remodeling of the collagen network is
an early event in this model of canine OA. This is reﬂected
by a decrease in collagen content and hydroxypyridinium
crosslink density of the cartilage tissue29,30. In addition,
there is also an increase in the cartilage content and
synovial ﬂuid levels of type II collagen neoepitopes that are
generated by cleavage of the alpha chains by any one of
the three collagenases (MMP-1, MMP-8 and MMP-13),
which are all produced by chondrocytes35,36. The cleavage
and denaturation of type II collagen, the most abundant
collagen of cartilage matrix, is likely to be a major event in
the pathophysiology of the OA process. Damage to the
collagen network is believed to be difﬁcult to repair and,
when signiﬁcant, is thought to herald irreversible progress
toward articular cartilage destruction. Accordingly, our
ﬁnding that CT reduced a net loss of collagen from cartilage
of OA knees may be of great clinical importance. It is
supported by previous in vitro studies25,27 showing that the
hormone not only increases the production of type II
collagen by human articular chondrocytes, but also inhibits
the collagenase activity present in the culture medium of
OA chondrocytes either by decreasing the activation of pro-
collagenases and/or by increasing the levels of tissue
inhibitors of metalloproteinases (TIMPs).
In summary, the results of the microscopic and bio-
chemical analyses demonstrate that the daily intra-nasal
administration of 400 units of CT signiﬁcantly reduces the
severity of most OA changes in the cruciate-deﬁcient knee.
Accordingly, this form of treatment, which most likely targets
different compartments of the joint, may be beneﬁcial for
humans who recently experienced a traumatic knee joint
injury and for dogs that have spontaneously ruptured their
anterior cruciate ligament.
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